Sanguine Resources

News | Events | Case Studies | Spotlight

Contributing to Medical Research for a Better Understanding of COVID-19

Sanguine Bioscience, a California-based biotechnology company focused on patient recruitment, sample collection engagement and digital health, has partnered with multiple biotech and pharmaceutical companies, such as Vir Biotechnology and EpiVax, Inc, to facilitate the patient recruitment for over 23 research studies, studies aimed at gaining a better understanding of COVID-19.

Researching COVID-19

We at Sanguine Bioscience have partnered with multiple biotech and pharmaceutical companies, such as Vir Biotechnology and EpiVax, Inc, to facilitate over 23 research studies aimed at gaining a better understanding of COVID-19. Although the overarching goal of this research is to develop treatments and vaccines, valuable information can be obtained about the virus, its patterns of infection, and the effectiveness of community response to the epidemic. 

Sanguine Bio Accelerates Pace in Vaccine Race

Biotech: Blood samples are raw materials for virus research and development. by Amy Stulick, Staff Reporter As pharmaceutical labs race to develop a vaccine for COVID-19, biomaterial for researchers has become increasingly valuable. That works to the advantage of Sanguine Biosciences in Sherman Oaks, which provides blood, tissue, plasma, and other biologic material for R&D.

Overcoming Longitudinal Study Challenges in Medical Research

Longitudinal studies are powerful tools in medical research armamentarium. Researchers gain valuable information following the same group of people with repeated measured variables over time. This type of research provides rates of change of continuous variable(s) over weeks, months, or years allowing researchers to assess patterns in human behavior or cause and effect relationships.

COVID and the Microbiome

Research on the human microbiome has burgeoned in recent years. Microbiome imbalances have been linked to chronic conditions, such as diabetes, cardiovascular disease, and depression. But scientists have also uncovered evidence of the microbiome’s crucial role in infectious diseases, including COVID-19, pointing to it as a promising target for treating them. 

Overcoming Study-Patient Burdens in Medical Research During the Pandemic

Study-patient recruitment and retention continue to be significant challenges in medical research, and even more so, during the COVID-19 pandemic. The at-home isolation and social distancing orders for millions of Americans is a vital element to slow the COVID-19 pandemic, but the global pandemic has the potential to disrupt and delay vital research.

The Benefits and Challenges of Real-World Data to Support Traditional Clinical Trial Initiatives

Historically, medical research data obtained from other sources outside of traditional clinical trials were viewed with a heavy dose of skepticism even before evaluation of the methodology. Although this real-world data (RWD) was widely used to satisfy safety monitoring and post-drug approval regulation requirements, many clinicians viewed RWD and the real-world evidence (RWE) it generated as unverified and unreliable data mining explorations with drug marketing objectives.

COVID-Sparked Practices Driving New Patient-Centric Behaviors

In 2000, Malcolm Gladwell’s The Tipping Point became a runaway bestseller by describing the factors that fuel an epidemic, and how the world suddenly becomes a different place as it reaches the inflection point. He discusses epidemics as spreading quickly like a virus, causing people to start behaving differently, triggering contagiousness, whether it applies to fashion trends, the uptake of cell phones, or the spread of disease.

Hemolysis: It’s Destruction!

Hemolysis is the rupture of red blood cells, and it has multiple causes, can happen at any time, both in vivo and in vitro.    Hemolysis Can Endanger Your Results Hemolysis can certainly impact study results, and has a particularly well-documented impact on potassium concentration measurements.